Seek Returns

RGEN vs. SNY: Repligen vs. Sanofi Stock Comparison

How do Repligen (RGEN) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Repligen (RGEN) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RGEN is classified in Life Sciences Tools & Services while SNY is classified in Pharmaceuticals.

Repligen (RGEN) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Repligen (RGEN) and Sanofi (SNY)
Profile ItemRGENSNY
NameRepligen CorporationSanofi ADR
Country/RegionUnited StatesFrance
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization11.09 billion USD112.71 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateApril 29, 1986July 1, 2002
Security TypeCommon StockADR

Price Performance

Cumulative Growth

RGEN
SNY
GSPC
Loading price history…
Repligen (RGEN) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Repligen (RGEN) and Sanofi (SNY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Repligen (RGEN) and Sanofi (SNY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Repligen (RGEN) and Sanofi (SNY)
MetricRGENSNY
Total Return (1Y)23.28%2.73%
Total Return (3Y, Annualized)6.20%6.89%
Total Return (5Y, Annualized)-8.41%3.16%

Risk Profile

Drawdown History

RGEN
SNY
GSPC
Loading price history…
Repligen (RGEN) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Repligen (RGEN) and Sanofi (SNY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Repligen (RGEN) and Sanofi (SNY)
MetricRGENSNY
Volatility (1Y, Annualized)46.73%23.60%
Beta (5Y)1.110.28
Max Drawdown (5Y)-64.67%-33.52%
Avg. Volume (3M)1.18M3.29M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
RGEN and SNY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Repligen (RGEN) and Sanofi (SNY)
MetricRGENSNY
Sharpe Ratio (1Y)0.41-0.07
Sortino Ratio (1Y)0.60-0.10

Profitability

ROE (TTM)

Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Sanofi (SNY) reports 5.72%, ranking against industry peers normally.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max
109.18%
Q3
6.23%
RGEN
-0.57%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.72%

Max
109.18%
Q3
6.23%
SNY
5.72%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Sanofi (SNY) reports 8.20%, ranking against industry peers normally.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max
18.05%
Q3
4.78%
Median
0.00%
RGEN
-1.47%
Q1
-4.14%
Min
-17.05%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.20%

Max
18.05%
SNY
8.20%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Sanofi (SNY) at 30.89% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max
83.12%
Q3
14.77%
RGEN
6.19%
Median
0.00%
Q1
-78.82%
Min
-207.40%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.89%

Max
83.12%
SNY
30.89%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Repligen (RGEN) and Sanofi (SNY)
MetricRGENSNY
ROE (TTM)-0.57%5.72%
ROA (TTM)1.40%5.31%
Net Margin (TTM)-1.47%8.20%
Operating Margin (TTM)6.19%30.89%
Gross Margin (TTM)53.77%73.68%

Growth

Revenue Growth

Both Repligen (RGEN) at 16.36% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Sanofi (SNY) reports EPS growth of 39.43%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.

Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Repligen (RGEN) and Sanofi (SNY)
MetricRGENSNY
Revenue Growth (YoY)16.36%5.49%
Revenue Growth (3Y CAGR)-2.70%4.82%
EPS Growth (YoY)--39.43%
EPS Growth (3Y CAGR)-35.73%6.02%

Financial Strength

Current Ratio (MRQ)

Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max
25.13
Q3
12.13
RGEN
9.88
Median
5.52
Q1
2.47
Min
0.10

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
SNY
1.12
Min
0.10
Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Repligen (RGEN) at 0.33 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max
1.42
Q3
0.65
RGEN
0.33
Median
0.15
Q1
0.02
Min
0.00

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.27

Max
1.42
Q3
0.65
SNY
0.27
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Repligen (RGEN) and Sanofi (SNY)
MetricRGENSNY
Current Ratio (MRQ)9.881.12
Debt / Equity (MRQ)0.330.27
Net Debt / EBITDA-1.190.96

Dividends

Dividend Yield (TTM)

Neither Repligen (RGEN) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Repligen (RGEN) pays no dividend (payout 0.00%).

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

119.86%

SNY
119.86%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Repligen (RGEN) and Sanofi (SNY)
MetricRGENSNY
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%119.86%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Sanofi (SNY) trades at 23.40 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RGEN
--

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.40

Max
85.34
Q3
43.46
Median
26.69
SNY
23.40
Q1
13.30
Min
0.07
Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): RGEN does not report P/E ratio, so it has no value marker; SNY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Repligen (RGEN) at 13.77 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max
58.18
Q3
25.77
RGEN
13.77
Median
7.30
Q1
3.01
Min
0.01

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.21

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
SNY
2.21
Min
0.01
Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Repligen (RGEN) at 4.70 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max
13.53
Q3
6.54
RGEN
4.70
Median
3.25
Q1
1.69
Min
-5.59

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
SNY
1.38
Min
-5.59
Loading chart…
Repligen (RGEN) vs. Sanofi (SNY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Repligen (RGEN) and Sanofi (SNY)
MetricRGENSNY
P/E Ratio (TTM)--23.40
P/S Ratio (TTM)13.772.21
P/B Ratio (MRQ)4.701.38
Free Cash Flow Yield (TTM)1.01%7.17%